Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 7835016 | A method for classification of the posterior atlanto-axial subluxation. | 1994 Sep | Atlanto-axial subluxation and dislocation in rheumatoid arthritis is a multidirectional abnormality. The most common subluxations take place anteriorly, vertically or laterally. Posterior atlanto-axial subluxations are rare. The distance between a line tangential to the anterior aspect of the axis (C2) and the most posterior aspect of the anterior arch of the atlas (C1) could be used to measure the displacement in posterior atlanto-axial subluxation. Routine measurement of this distance could give us a better idea of the frequency of this type of affection in rheumatoid arthritis of the cervical spine. Serial measurements might be used to estimate the progression of the disease. | |
| 8150387 | [Treatment of palmar dislocation and ulnar deviation of the metacarpophalangeal joint in c | 1994 Jan | In rheumatoid arthritis, a number of surgical procedures address the pathology at the metacarpophalangeal joint level. Besides synovialectomy, the use of endoprothetics is widespread. Particularly during the last years, more importance has again been attached to resection arthroplasty technique (e.g. Vainio's technique). The authors introduce a modified technique of Vainio's resection arthroplasty, permitting an active reposition of the proximal phalanx from its previous palmar dislocation and ulnar deviation. First clinical experience confirms the efficacy of this modified technique. | |
| 1433000 | Cyclosporine A for the treatment of necrotizing scleritis and corneal melting in patients | 1992 Sep | Two of the ocular complications of rheumatoid arthritis (RA), necrotizing scleritis and keratolysis, have been associated with poor response to standard ocular therapy, and thus poor ocular outcome. We describe 6 patients with active ocular disease and active RA who failed to respond to disease modifying agents or immunosuppressive therapy and whose ocular and arthritic disease subsequently responded to cyclosporine A. Drug related complications were consistent with those reported for patients receiving similar doses for RA. | |
| 8504321 | The role of exercise in the treatment of inflammatory arthritis. | 1993 Feb | A routine of regular exercise is important in patients with inflammatory arthritis. Most patients with stage I and stage II RA are capable of engaging in an exercise program. Benefits include increased cardiovascular and muscle endurance, as well as improved muscle strength (Table 1). This in turn allows patients to function more independently and with an improved quality of life. Exercise programs are designed to restore range of motion, improve strength and endurance, and at the same time provide a social outlet and opportunity for improved self esteem. Exercises should progress slowly during which time patients should be closely monitored for symptoms of increased joint inflammation. | |
| 7721556 | Balneotherapy for rheumatoid arthritis at the Dead Sea. | 1995 Apr | Thirty-six patients with active rheumatoid arthritis were treated for 12 days at the Ein Gedi Spa. The patients were allocated randomly to four study groups. Group 1 (n = 9) was treated with daily baths in the Dead Sea, group 2 (n = 9) was treated with daily sulphur baths, group 3 (n = 10) was treated with a combination of daily Dead Sea bathing and sulphur baths, and group 4 (n = 8) served as a control group. All patients were assessed by a rheumatologist who was blinded to the treatment modalities and group allocation. Clinical parameters assessed included: duration of morning stiffness, 15 m walk time, grip strength, activities of daily living, patient's assessment of disease severity, number of active joints, and the Ritchie articular index. Statistically significant improvement lasting up to 3 months was observed only in the three treatment groups. | |
| 7858576 | [Functional ability and quality of life in rheumatoid arthritis: use of the Functional Ind | 1994 Dec | Functional disability and quality of life were evaluated using the Functional Independence Measure and the Reintegration to Normal Living Index, respectively, in 57 subjects (15 men and 42 women) with a mean disease duration of 15 years. Scores on both these nonspecific scales correlated with those obtained using instruments specifically designed for rheumatoid arthritis (ARA index, Lee index) and with a number of clinical parameters including patient age, disease duration and number of affected joints. Functional ability was correlated with quality of life in this study and in others performed using other evaluation tools. Nonspecific assessment scales are useful for comparing function and quality of life in various diseases. | |
| 1288925 | [Experimental study on the influence of acupuncture and moxibustion on interleukin-2 in pa | 1992 | Rheumatoid arthritis (RA) is referred to the category of Bi syndromes in traditional Chinese medicine. It is regarded as an autoimmune disease, but the pathogenic mechanism is still to be clarified. In order to observe the effects of the treatment of RA with acupuncture and moxibustion on IL-2, 41 patients were divided into warming needle and point injection groups at random, and 19 healthy subjects as control group. The results showed that the IL-2 levels in two RA groups before treatment were obviously lower than that in control group (P 0.05). After treatment the IL-2 level in control group was unchanged, but increased considerably in two RA groups (P 0.01). Generally, IL-2 is considered as a very important signal for regulating immune response. Our results have shown that the decrease of IL-2 in patients with RA should be one of main causes of internal environment disorder, acupuncture and moxibustion as a stress stimulation exerts an influence on the immunity system through neuroendocrine system to improve the IL-2 production. | |
| 8882023 | Serum phospholipase A2 activity in patients with rheumatoid arthritis before and after tre | 1996 Feb | OBJECTIVE: (1) To confirm a previous observation that serum phospholipase A2 (PLA2) activity correlates with disease activity in rheumatoid arthritis (RA); and (2) to determine whether serum PLA2 activity changes after treatment with methotrexate (MTX), auranofin (AF), or a combination of the 2 (COMBO). METHODS: Sera obtained at baseline and after treatment from 100 patients with RA (40 MTX, 32 AF, and 28 COMBO) who participated in a multicenter, double blind trial were tested for PLA2 activity using an assay that measures the release of radiolabeled 14C oleic acid from the cell membrane of Escherichia coli. Detailed statistical analysis was performed using previously collected clinical data to determine whether correlations exist between RA disease activity and serum PLA2 activity; whether baseline serum PLA2 activity predicted a therapeutic response in any treatment group; and whether there was a significant change in serum PLA2 activity after treatment in patients who responded to the various drugs. RESULTS: Baseline serum PLA2 activity was significantly increased in patients with RA compared to healthy controls. No correlation between serum PLA2 activity and RA disease activity was noted at baseline. Mean serum PLA2 activity did not change significantly after treatment with MTX, AF, or COMBO in either treatment responders or nonresponders. CONCLUSION: Serum PLA2 activity is increased in patients with RA compared to healthy controls, but does not correlate with disease activity in patients, nor does it predict a response to treatment with MTX, AF, or COMBO. Serum PLA2 activity also did not change significantly after treatment with any of the above agents. | |
| 8308771 | Prospective 5-year followup of recombinant interferon-gamma in rheumatoid arthritis. | 1993 Nov | OBJECTIVE: To define clinical and laboratory outcomes of longterm recombinant interferon-gamma (rIFN-gamma) treatment of patients with rheumatoid arthritis (RA). METHODS: Patients with RA (70) completing a 12-week multicenter double blind trial comparing rIFN-gamma with placebo were enrolled in a longterm prospective protocol evaluating rIFN-gamma in RA. RESULTS: The majority of patients sustained clinical improvement for one year. Eight (11%) patients with RA continued to receive rIFN-gamma after 5 years. One patient fulfilled remission criteria. rIFN-gamma was well tolerated with remarkably few suspected adverse drug reactions. Forty-seven (67%) patients discontinued rIFN-gamma because of lack of efficacy, 7 (10%) because of concurrent illnesses, 5 (7%) were not compliant to study protocol, 3 (4%) developed suspected adverse drug reactions for a total of 62 (89%) withdrawals over the 5 years of followup. Patients continuing rIFN-gamma treatment for 5 years had lower initial total leukocyte and neutrophil counts and higher hemoglobin and hematocrit levels than patients who discontinued rIFN-gamma during the 5-year followup. CONCLUSIONS: Longterm treatment of RA with rIFN-gamma was generally well tolerated. Although many patients maintained sustained clinical improvement for at least one year, the main reason for discontinuing the drug over 5 years was the lack of continued benefit. | |
| 8323378 | Rheumatoid arthritis, HLA identity, and age at menarche. | 1993 May | OBJECTIVE: To determine whether women with rheumatoid arthritis (RA) had differences in obstetric and gynaecological histories when compared with sisters without RA (controls) METHODS: Ninety eight RA discordant sister pairs, 36 of whom were identical for histocompatibility locus antigen (HLA-A, HLA-B, and HLA-Cw) types, were asked to recall their age of menarche, duration of use of contraceptive pill, pregnancy history, and age of menopause. RESULTS: The 98 siblings with RA had an older mean age of menarche (13.90 (95% confidence interval (95% CI) 13.56 to 14.24) years) than their sisters (13.49 (95% CI 13.22 to 13.76) years; mean difference within pairs 0.41, 95% CI 0.09 to 0.73 years, paired t test t = 2.54, p = 0.013). When the pairs were divided into identical HLA and non-identical HLA groups, the first showed no significant difference (mean difference 0.17 (95% CI -0.40 to 0.73) years), whereas the second did (mean difference 0.55 (95% CI 0.16 to 0.94) years, t = 2.80, p = 0.007). A multiple regression analysis to predict differences in menarche in the non-identical HLA sibling pairs failed to show any demographic or reproductive confounding variables. In 19 RA concordant sibling pairs, the seven HLA identical pairs had similar ages of menarche, whereas the 12 non-identical HLA pairs had interpair differences that narrowly missed significance (p = 0.054). All other obstetric and gynaecological variables were not significantly different within the pairs. CONCLUSIONS: The interpretations of these results are that either delayed menarche may predispose to or act as a marker of RA, or HLA linked genes are important in determining the age of menarche irrespective of disease state. This study fails to support a significant role for other obstetric and gynaecological variables in RA. | |
| 8345275 | The Guildford elbow. | 1993 Jun | The Guildford elbow is a new unconstrained elbow arthroplasty. From 1985 to 1991, this arthroplasty was used in 24 patients with rheumatoid arthritis. The patients were reviewed after an average of 28 months (4-59 months). Good to excellent results were obtained in 95% regarding pain relief and functional improvement. Complications were few, with only one case of clinical loosening and three of radiological loosening. Ulnar nerve hypo-aesthesia was common but did not jeopardize the final result in any patient. | |
| 8849377 | The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. | 1996 Feb | OBJECTIVE: To determine whether the mortality of patients with rheumatoid vasculitis (RV) is increased in comparison with that of patients with rheumatoid arthritis (RA). METHODS: The mortality of all RV patients identified in 1980-1992 (n=61) was compared with that of 244 RA controls matched for the year the diagnosis was made in the RV cases. Hazard ratios (HR) of death were calculated with a multivariate survival analysis, adjusting for age, sex, comorbidity, treatment, and parameters of RA severity. RESULTS: The unadjusted risk of death (HR) in RV patients compared with RA controls was 1.65 (95% confidence interval [95% CI] 1.05-2.58). After adjustment for prognostic factors, the HR was reduced to 1.26 (95% CI 0.79-2.01), mainly due to removal of the effects of age and sex. No excess mortality was seen in RV patients with severe organ involvement when compared with RV patients without severe organ involvement, although the former patients were treated more often with cytostatic and immunosuppressive drugs. Infection was the main cause of death in the RV patients, and cardiovascular disease in the RA controls. Vasculitis was reported as the cause of death in only 1 RV patient. CONCLUSION: After allowance for general risk factors such as age and sex, there remains only a slight excess mortality in RV patients compared with RA controls. | |
| 8233233 | A comparative study of labelled neutrophil behaviour in patients with rheumatoid arthritis | 1993 Oct | A comparative study of neutrophil pharmacokinetics and distribution between normal volunteers and patients with rheumatoid arthritis (RA) is presented. White cell viability was confirmed by prominent localization of activity in the spleen with minimal liver uptake and lack of retention in the lungs in both normal volunteers and RA patients. There were no significant differences between both groups in granulocyte clearance from the lungs and their subsequent distribution in the spleen, bone marrow and liver. The results of this study demonstrate that the behaviour of granulocytes in RA patients is essentially unchanged from that of normal volunteers. | |
| 8151583 | Cause of death in 81 autopsied patients with rheumatoid arthritis. | 1994 Jan | OBJECTIVE: To evaluate the cause of death and complications in a series of autopsied patients with rheumatoid arthritis (RA). METHODS: A clinicopathological study of 81 autopsied patients with RA was performed. RESULTS: In order of frequency, the causes of death were infection (23.5%), heart disease (17.3%), respiratory failure (9.9%), renal failure (9.9%), and gastrointestinal disease (9.9%). Observed complications of RA were systemic angiitis in 25 cases (30.8%), systemic amyloidosis in 17 cases (21.0%), and pulmonary fibrosis in 28 cases (34.6%). No patient had both angiitis and amyloidosis simultaneously. The prevalence of systemic angiitis tended to decrease during the study period (1960-1990), while systemic amyloidosis tended to increase. CONCLUSION: The cause of death in RA is difficult to analyze accurately because RA itself is a chronic systemic inflammation disease. | |
| 8565719 | [Antikeratin antibodies: another specific antibodies in rheumatoid arthritis patients]. | 1995 May | Sera from 107 patients with rheumatoid arthritis (RA), 120 patients with other rheumatic diseases and 60 blood donors were tested with indrect immunofluorescence on the middle third of Wistar rat oesophagus as a substrate for the presence of antikeratin antibodies (AKA). By labelling the stratum corneum and stratum spinosum with IgG antibodies, three patterns of reaction were distinguished. Among them, only one pattern which showed an intense linear laminated fluorescence on stratum corneum and a weak fluorensence on stratum spinosum was valuable for the diagnosis of RA, with a specificity of 99% and a sensitivity of 23%. It was also found that they were not related to the presence of rheumatoid factor or anti-RA 33,000/36,000 antibodies. Thus, AKA might be another marker antibody in RA. | |
| 8523338 | Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. | 1995 Sep | OBJECTIVE: To determine the efficacy and safety of a platelet activating factor (PAF) antagonist, BN 50730, in patients with rheumatoid arthritis. METHODS: Ten patients with an active disease were treated for 4 weeks with a PAF receptor antagonist, BN 50730, given orally (40 mg twice daily). The treatment period was followed by a 4 weeks followup period. RESULTS: Clinical indicators of disease activity significantly improved during the treatment period, with a progressive return to baseline values during the followup period. No significant change in laboratory variables was observed. The tolerance of the treatment was excellent, and no clinical or laboratory evidence of side effects was recorded. CONCLUSION: These results need to be confirmed in a controlled study, but suggest an antiinflammatory effect. PAF antagonists could represent a new class of therapeutic agents in inflammatory arthropathies. | |
| 7770497 | Rheumatoid arthritis: status of drug therapies. | 1995 Jun | This article describes the current drug therapies used to manage rheumatoid arthritis (RA). A brief description of the pathology, pathogenesis, and clinical features of RA is presented. The purpose of the article is to increase an awareness among physical therapists regarding the medications their patients might be taking and how these agents might influence the outcome of physical therapy intervention. The general approach to prescribing medication is presented according to the status of the disease. The attributes of nonsteroidal antiinflammatory drugs, corticosteroids, slow-acting antirheumatic drugs, and cytotoxic and experimental drugs used in RA are described. Given the potential benefits, side effects, and adverse reactions of these potentially powerful medications, it is important for the physical therapist to monitor closely what is happening to the patient with respect to the use or nonuse of the medication. | |
| 1617904 | HLA typing and seropositivity in Finnish and in Polish patients with rheumatoid arthritis | 1992 Jun | We determined HLA-A, -B, -C and -DR antigens in 83 patients with rheumatoid arthritis (RA) and reactive secondary amyloidosis (RSA), 60 in Finland and 23 in Poland, and compared the results with control RA patients and blood donors. There were no significant differences in the frequencies of HLA between the RA patients with and those without RSA in either Finland or Poland, and no significant differences between the Finnish and Polish patients with RSA. All the RSA patients from Finland and 70% of the RSA patients from Poland were seropositive. In the development of RSA, the prolonged period of inflammatory stimuli may play a more important role than genetic factors. | |
| 8124914 | Rheumatoid arthritis in a population sample in the Gulf: clinical observations. | 1993 Dec | In our practice we had constantly been under the impression that most Arab patients with RA tend to have a non-aggressive and rather nondisabling disease. Therefore, the spectrum of RA was studied in 42 hospital patients with classic or definite forms. Their mean age was 41.2 years and the mean duration of illness was 5.25 years. F:M ratio was 3.6:1. Seropositivity and radiological findings were observed in 59.5% and 45.2% of the patients respectively. They showed a marked lack of nonarticular manifestations with insignificant functional incapacity. The over-all assessment appeared to be in agreement with the initial clinical impression. | |
| 1417133 | Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind | 1992 Sep | Interferon gamma (IFN gamma) has been advocated in open studies as a beneficial remission inducing drug for the treatment of rheumatoid arthritis (RA). The work reported here was designed to assess the therapeutic potential of IFN gamma in the treatment of RA in a double blind placebo controlled study. It was found that patients treated with IFN gamma improved significantly with respect to morning stiffness, grip strength, swelling of an index joint, and erythrocyte sedimentation rate. Furthermore significantly more responders (according to predetermined response criteria) were found in the group treated with IFN gamma. Only minor adverse effects and no significant toxicity with respect to clinical or laboratory parameters were observed. |